PT3166933T - Compostos de epoxicetona para inibição de enzimas - Google Patents

Compostos de epoxicetona para inibição de enzimas

Info

Publication number
PT3166933T
PT3166933T PT15821964T PT15821964T PT3166933T PT 3166933 T PT3166933 T PT 3166933T PT 15821964 T PT15821964 T PT 15821964T PT 15821964 T PT15821964 T PT 15821964T PT 3166933 T PT3166933 T PT 3166933T
Authority
PT
Portugal
Prior art keywords
enzyme inhibition
epoxyketone compounds
epoxyketone
compounds
inhibition
Prior art date
Application number
PT15821964T
Other languages
English (en)
Portuguese (pt)
Inventor
Yang Jinfu
James Cen Jian
Michelle Fan Xiaoqing
Original Assignee
Centrax Int Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centrax Int Inc filed Critical Centrax Int Inc
Publication of PT3166933T publication Critical patent/PT3166933T/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06078Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0802Tripeptides with the first amino acid being neutral
    • C07K5/0804Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0821Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
PT15821964T 2014-07-14 2015-07-14 Compostos de epoxicetona para inibição de enzimas PT3166933T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462024024P 2014-07-14 2014-07-14

Publications (1)

Publication Number Publication Date
PT3166933T true PT3166933T (pt) 2018-12-06

Family

ID=55079165

Family Applications (1)

Application Number Title Priority Date Filing Date
PT15821964T PT3166933T (pt) 2014-07-14 2015-07-14 Compostos de epoxicetona para inibição de enzimas

Country Status (10)

Country Link
US (2) US10640533B2 (enExample)
EP (1) EP3166933B1 (enExample)
JP (1) JP6608442B2 (enExample)
KR (2) KR102462240B1 (enExample)
CN (1) CN105960399B (enExample)
DK (1) DK3166933T3 (enExample)
ES (1) ES2704056T3 (enExample)
PT (1) PT3166933T (enExample)
TR (1) TR201816372T4 (enExample)
WO (1) WO2016011088A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3166933B1 (en) 2014-07-14 2018-08-01 Centrax International Inc. Epoxyketone compounds for enzyme inhibition
US20240092831A1 (en) * 2019-10-11 2024-03-21 Mayo Foundation For Medical Education And Research Proteasome Inhibitors
CN118255835A (zh) * 2022-12-27 2024-06-28 上海美悦生物科技发展有限公司 三肽环氧酮化合物、药物组合物及其制备方法和用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005105827A2 (en) * 2004-04-15 2005-11-10 Proteolix, Inc. Compounds for proteasome enzyme inhibition
AU2005243140A1 (en) * 2004-05-10 2005-11-24 Proteolix, Inc. Synthesis of amino acid keto-epoxides
WO2006063154A1 (en) * 2004-12-07 2006-06-15 Proteolix, Inc. Composition for proteasome inhibition
EP2623113B1 (en) 2005-11-09 2017-05-31 Onyx Therapeutics, Inc. Compound for enzyme inhibition
WO2008140782A2 (en) * 2007-05-10 2008-11-20 Proteolix, Inc. Compounds for enzyme inhibition
KR20110073584A (ko) 2008-10-21 2011-06-29 오닉스 세라퓨틱스, 인크. 펩티드 에폭시케톤과의 병용 요법
MX2012011604A (es) * 2010-04-07 2013-02-27 Onyx Therapeutics Inc Inhibidor de inmunoproteasoma de péptido epoxicetona cristalino.
EP4144354B1 (en) 2011-08-30 2025-11-26 Trustees Of Tufts College Fap-activated proteasome inhibitors for treating solid tumors
CA2879454A1 (en) 2012-07-19 2014-01-23 Drexel University Novel sigma receptor ligands and methods of modulating cellular protein homeostasis using same
WO2014018807A1 (en) * 2012-07-26 2014-01-30 Centrax International, Inc. Peptide epoxyketone compounds
JP2015526433A (ja) * 2012-08-14 2015-09-10 フルオリノブ ファーマ インコーポレイテッド フッ素化エポキシケトン系化合物、およびプロテアソーム阻害物質としてのその使用
CA2881986A1 (en) * 2012-08-21 2014-02-27 Fluorinov Pharma Inc. Fluorinated epoxyketone-based tetrapeptide compounds and uses thereof as proteasome inhibitors
EP3166933B1 (en) 2014-07-14 2018-08-01 Centrax International Inc. Epoxyketone compounds for enzyme inhibition

Also Published As

Publication number Publication date
US20170158734A1 (en) 2017-06-08
WO2016011088A2 (en) 2016-01-21
EP3166933B1 (en) 2018-08-01
KR20210093378A (ko) 2021-07-27
EP3166933A4 (en) 2017-07-19
US10640533B2 (en) 2020-05-05
KR20170041747A (ko) 2017-04-17
US20200087343A1 (en) 2020-03-19
WO2016011088A3 (en) 2016-08-11
EP3166933A2 (en) 2017-05-17
JP6608442B2 (ja) 2019-11-20
KR102462240B1 (ko) 2022-11-03
KR102360356B1 (ko) 2022-02-08
ES2704056T3 (es) 2019-03-14
CN105960399A (zh) 2016-09-21
CN105960399B (zh) 2018-09-25
JP2017522383A (ja) 2017-08-10
TR201816372T4 (tr) 2018-11-21
DK3166933T3 (en) 2018-11-26
US10787482B2 (en) 2020-09-29

Similar Documents

Publication Publication Date Title
IL287113A (en) smyd inhibitors
GB201421083D0 (en) Enzyme inhibitors
IL246785A0 (en) Benzimidazole-2-amines as midh1 inhibitors
GB201421088D0 (en) New enzyme inhibitors
EP3116503A4 (en) Hptp-beta inhibitors
EP3099695A4 (en) Compounds
GB201416446D0 (en) New enzyme inhibitor compounds
SG11201610904UA (en) Syk inhibitors
EP3224246A4 (en) 4-oxoquinoline compounds
IL248895A0 (en) Phosphatidylinositol 3-kinase inhibitors
EP3099694A4 (en) Compounds
EP3172208A4 (en) Compounds
EP3142667A4 (en) Methods for inhibiting necroptosis
GB201421085D0 (en) New enzyme inhibitors
GB201403536D0 (en) Inhibitor compounds
EP3110792A4 (en) Aminocarbonylcarbamate compounds
AP2017009778A0 (en) Azetidinyloxyphenylpyrrolidine compounds
EP3149010A4 (en) Monoaminosilane compounds
GB201415429D0 (en) Corrosion inhibition
EP3227470A4 (en) Corrosion inhibition
EP3190891A4 (en) Substituted cyclohexylamine compounds
PT3166933T (pt) Compostos de epoxicetona para inibição de enzimas
EP3213751A4 (en) Phacosclerosis inhibitor
GB201415614D0 (en) Corosion Inhibition
GB201401005D0 (en) Inhibitor